Brands
Engineered to Impress as Liebherr Privé Redraws India’s Luxury Blueprint
MUMBAI: Luxury in India has finally traded the glitter for the gears and Liebherr Privé made sure everyone noticed. In an evening where design met discipline and innovation met intention, Liebherr Appliances India and Network18 unveiled an invite-only showcase that signalled a bold shift, luxury that thinks before it shines. The night opened on a note as rich as its theme Purbayan Chatterjee’s sitar weaving a meditative calm through a room filled with global leaders, architects, innovators, and cultural tastemakers. It set the stage for a celebration not of excess, but of intelligence, engineering, and human-centred design.
Network18’s anchor welcomed guests before Liebherr Appliances India MD of sales Kapil Agarwal framed the agenda: a commitment to precision engineering, sustainability-led design and products built for the way India lives, evolves, and aspires. “Innovation is not about complexity; it’s about purpose,” Kapil said, emphasising how design aligned with real human needs can elevate daily life rather than merely ornament it.
At the heart of the evening was the Liebherr Foundational Fireside, a sharply insightful exchange featuring Steffen Nagel and Roman Schäfer in conversation with CNBC-TV18’s Manisha Gupta. Together, they unpacked Liebherr’s legacy of uncompromising build quality, intelligent technology, and long-term commitment to India, a market they described as “growing at a speed no other market can match.”
Steffen set the tone: “Innovation for us is embedded in our DNA… whether it is quality, functionality or sustainability, we see it as our responsibility to create products that add value while ensuring the next generation inherits a better world.” Roman echoed the sentiment, noting, “We don’t copy-paste Europe for India; it is with India, for India, and now from India to the world. The future of luxury is not loud, it is seamless.”
The conversation seamlessly expanded into real estate and lifestyle, with a special fireside conversation featuring HoAL chairman Abhinandan Lodha. Under the theme “From Square Feet to Smart Living,” Lodha explored how engineering-led innovation is reshaping luxury homes. “India’s luxury consumer is younger, sharper and demanding real quality,” he said, highlighting HoAL’s data-driven approach powered by 1,45,000 verified insights. “Sustainability costs more, but it’s our duty to the next generation.”
The showcase then moved into a high-energy panel on the future of evolving homes, gathering voices from architecture, interiors, arts, and design including Rajiv Mishra, Sumisha Gilotra, Brinda Miller, Nisha JamVwal and Neelam Sonavane. The discussion painted a vivid picture of how culture, functionality, and emotional resonance are redefining Indian homes.
But the evening’s most anticipated moment belonged to the powerhouse duo Sussanne Khan and Farah Khan Ali. Their conversation, “Designing Modern Luxury Where innovation meets personal expression,” blended vulnerability, vision, and wit. Sussanne said, “Modern luxury is a marriage of technology and emotion: a home with a heart and a brain.” From artisanal craft to smart automation, from eco-materials to soulful storytelling, she outlined a design philosophy deeply rooted in warmth, creativity and intuition.
As India steps confidently into an era of intelligent, future-ready living, Liebherr Privé stood as more than a curated evening, it became a manifesto. A reminder that the next chapter of luxury will be engineered, intentional and quietly extraordinary. A world where timeless craftsmanship meets intelligent technology, and where design doesn’t just decorate life, it deepens it.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
